Forsteo ® (teriparatide)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Forsteo Summary of Product Characteristics (SmPC)

Forsteo® (teriparatide): Administration on Alternate Days

Forsteo is not registered for administration on alternate days and this type of dosing is not recommended. Lilly-sponsored clinical trials have only evaluated the efficacy and safety of once-daily administration of teriparatide

Further Information

When the individual clinical decision was made to start a treatment with teriparatide in a patient, the recommended dose is 20 mcg teriparatide once daily since the summary of product information does not list other doses of teriparatide for particular situations or specific patient populations.1

Posology according to Summary of Product Characteristics

The recommended dose of Forsteo is 20 micrograms administered once daily.1

The maximum total duration of treatment with Forsteo should be 24 months. The 24-month course of Forsteo should not be repeated over a patient’s lifetime.1

Patients should receive supplemental calcium and vitamin D supplements if dietary intake is inadequate.1

Following cessation of Forsteo therapy, patients may be continued on other osteoporosis therapies.1

References

1. Forsteo [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

Date of Last Review: February 10, 2020

Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 8am - 4pm, excluding Bank Holidays

Or you can

Ask us a question Chat with Us If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a question